Dyadic International (NASDAQ:DYAI) and Wave Sync (OTCMKTS:WAYS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
Earnings & Valuation
This table compares Dyadic International and Wave Sync’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Dyadic International||$760,000.00||215.10||-$2.14 million||N/A||N/A|
|Wave Sync||$90,000.00||14.02||-$5.61 million||N/A||N/A|
This table compares Dyadic International and Wave Sync’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and price targets for Dyadic International and Wave Sync, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Dyadic International presently has a consensus target price of $9.00, indicating a potential upside of 49.25%. Given Dyadic International’s higher probable upside, equities research analysts plainly believe Dyadic International is more favorable than Wave Sync.
Volatility and Risk
Dyadic International has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Wave Sync has a beta of -1.09, indicating that its share price is 209% less volatile than the S&P 500.
Insider and Institutional Ownership
0.4% of Dyadic International shares are owned by institutional investors. 23.9% of Dyadic International shares are owned by company insiders. Comparatively, 42.5% of Wave Sync shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Dyadic International beats Wave Sync on 8 of the 9 factors compared between the two stocks.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corp. to express two therapeutic compounds using C1 production platform; and the Sanofi-Aventis Deutschland GmbH to express the potential of its C1 technology to produce various types of therapeutic compounds for manufacturing protein-based vaccine and biologic drugs; and research collaboration with global biotech company to explore the potential of its C1 technology to produce an active moiety. The company was founded in 1979 and is headquartered in Jupiter, Florida.
About Wave Sync
Wave Sync Corp., a development stage company, engages in the design, development, and proliferation of next generation debit and credit cards for financial institutions in the United States. The company offers its products by employing secured encryption transmitted through audio wave technology. It also supplies and sells electronic inlays embedded with audio chips and other modules to card manufacturers. The company is based in Randolph, New Jersey.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.